Virtual Library
Start Your Search
J.C. Garibay-Diaz
Author of
-
+
P3.02b - Poster Session with Presenters Present (ID 494)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02b-107 - Efficacy of Afatinib and Gefitinib in Lung Adenocarcinoma with EGFR Gene Mutation as 2nd or 3rd Line Treatment (ID 4540)
14:30 - 14:30 | Author(s): J.C. Garibay-Diaz
- Abstract
Background:
In Mexico, 85% of patients with lung cancer are diagnosed in an advanced stage. The most effective current treatment is chemotherapy, however only 40% of patients respond to it. A substantial progress is the recognition of several distinct subgroups of Adenocarcinoma that respond differently according to mutations in oncogenes. Patients with EGFR mutation are optimally treated with EGFR tyrosine kinase inhibitors (TKIs). In Mexico, the access to oncologic medication is problematic due to poverty, socio-demographic problems and health access, which impedes treatment initiation with TKIs as first line therapy. We sought to confirm the beneficial effect of TKIs as second or third line therapy on patients with advanced stage lung cancer adenocarcinoma.
Methods:
In this retrospective, unicentric study we assigned 41 patients by convenience with lung adenocarcinoma in advanced clinical stage of the disease to receive afatinib or gefitinib as second or third line treatment. The primary end point of our trial is to describe progression free survival and global survival outcomes in patients that receive TKIs as second or third line therapy. Secondary end points were time elapsed from the beginning of TKIs to the time of response by RECIST 1.1, and toxicity between the two groups. Conflict of interest: Boehringer Ingelheim donated Afatinib and The National Institute of Respiratory Diseases in Mexico donated Gefitinib.
Results:
From 120 patients, 41 of them were selected to receive TKIs by convenience. The progression free survival with afatinib PFS was 11 months and 10 months for gefitinib, with no significant difference in both therapeutic groups (HR 0.79, p=0.173). There is a reduction in 2 years mortality in favor of afatinib (HR 0.69, p=0.046). There were no significant differences between afatinib and gefitinib in response rate, also there were no differences by RECIST 1.1. We observed more incidence of mucositis in the group treated with afatinib (HR 0.58, p=0.006) and metastasis to CNS at diagnosis observed in afatinib group (p= 0.029).
Conclusion:
There was a reduction in 2 years mortality with afatinib treatment compared with gefitinib. With the data obtained we can infer that TKIs show similar benefits in second and third line as if given at the beginning, with a good progression free survival, with no significant differences between afatinib or gefitinib.
